Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group



Shaygannejad V1 ; Montazeri S2 ; Gharagozloo M3 ; Tahani S4 ; Ashtari F1 ; Vesal S5 ; Hasheminia SJ3 ; Dehghani L5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine and Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biology, School of Medical Sciences, Najafabad Branch Islamic Azad University, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2013

Abstract

Background: Midkine (MK) is a heparin-binding growth factor with various effects in induction of neurodegenerative diseases and promotes inflammatory responses by enhancing the migration of inflammatory leukocytes. This study aimed to determine the relationship of Midkine protein and clinical course of multiple sclerosis (MS). Methods: In 32 patients with MS and 32 Age- and sex-matched healthy people, the serum level of Midkine and other cytokines (IL10, IL17, IL23 and TGF-β) were determined by enzyme-linked immunosorbent assay (ELISA) method and compared. Findings: Midkine level in patients with MS was significantly lower than healthy control. In addition, there were significant differences between IL10, IL23 and TGF-β levels in patients with MS and the healthy people. Conclusion: It seems that the significant lower level of Midkine in patients with MS is because of IFN-β treatment for them during this research.
Related Docs
View other Related Docs
1. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
2. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
3. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
4. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
5. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
6. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
7. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
8. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (81)
Vahid Shaygannejad (54)
Other Related Docs
9. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
10. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
11. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
12. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
13. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
14. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
15. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)
16. Leptin Hormone Level in Serum of Opticospinal, Neuromyelitisoptica and Multiple Sclerosis Patients, Clinical and Experimental Neuroimmunology (2014)
17. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
18. Expression and Clinical Significance of Il7r, Nfatc2, and Rnf213 in Familial and Sporadic Multiple Sclerosis, Scientific Reports (2021)
19. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
20. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
21. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
22. Multiple Sclerosis and Cerebral Endothelial Dysfunction: Mechanisms, Pathophysiology (2011)
23. Evaluation of Matrix Metalloproteinase-9 Plasma Levels in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their First-Degree Family, Metabolic Brain Disease (2021)
24. Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls, Immunological Investigations (2015)
25. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
26. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
27. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
28. Cytomegalovirus and Varicella Zoster Virus Seropositivity of Iranian Patients With Multiple Sclerosis: A Population-Based Study, Journal of Neuroimmunology (2017)
29. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
30. Insulin-Like Growth Factor-1 (Igf-1) Levels in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, PLoS ONE (2024)
31. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
32. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
33. Cd24 Gene Allele Variation Is Not Associated With Oligoclonal Igg Bands and Igg Index of Multiple Sclerosis Patients, NeuroImmunoModulation (2012)
34. The Effect of Ifn-Β Treatment on Plasma Levels of Bdnf and Il-6 in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2021)
35. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
36. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
37. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
38. Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe], Neurologia i Neurochirurgia Polska (2011)
39. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
40. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
41. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
42. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
43. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
44. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
45. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
46. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
47. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
48. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
49. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
50. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)